Feature

FDA approves subcutaneous immunoglobulin treatment for CIDP


 


The European Commission also recently granted marketing authorization for Hizentra based on the information from the PATH trial.

Hizentra was initially approved in the United States in 2010 for primary immunodeficiency in patients aged 2 years and older.

Since Hizentra is a self-administered drug, it is important for physicians to teach their patients how to properly inject this treatment without hitting a blood vessel. Apart from issues related to self-administration, the risk of thrombosis is also present, which is not uncommon for immune globulin products.

Next Article: